Reinhold-Keller Eva, Fink Claudia O E, Herlyn Karen, Gross Wolfgang L, De Groot Kirsten
Medical University of Lübeck, Lübeck, Germany.
Arthritis Rheum. 2002 Jun 15;47(3):326-32. doi: 10.1002/art.10459.
To examine the long-term efficacy of low-dose intravenous methotrexate (MTX) with and without concomitant glucocorticoids (GC) for remission maintenance in patients with generalized Wegener's granulomatosis (WG) in an open-label, prospective, standardized trial.
After induction of remission by cyclophosphamide and GC, 71 patients (41 males, 30 female) with initially generalized WG received low-dose methotrexate at 0.3 mg/kg body weight once weekly. At study-start 55 of 71 (77.5%) patients were on low-dose GC (mean 5.9 mg/day) which was tapered during the study. All patients underwent interdisciplinary staging at 3-month (and later at 6-month) intervals to assess disease activity and extent as well as side effects. End points were the first relapse or the end of study (January 2001).
Within a mean followup period of 25.2 months, 26 patients (36.6%) experienced a relapse after a mean of 19.4 months. Seventeen (65.4%) of these 26 patients had terminated GC therapy at the time of relapse. There was no difference in relapse rates among patients with and without concomitant GC at study start. Relapses occurred mainly in the initially involved organ systems, preferentially in the ear, nose and throat tract in 18 of 26 patients and the kidney in 16 of 26 patients. One renal relapse presented as rapid, progressive glomerulonephritis with lethal outcome. Further, 14 relapses were accompanied by a significant rise in creatinine values. In 15/26 patients the relapse was paralleled or preceded by a significant rise of antineutrophil cytoplasmic antibody titer. Two patients ceased MTX prematurely because of persistent leukopenia.
Weekly MTX is a well tolerated therapy for long-term maintenance of remission. However, one-third of the patients relapsed during ongoing MTX treatment, irrespective of whether they were still receiving GC. Because more than half of the relapses affected the kidney, close monitoring is indispensable.
在一项开放标签、前瞻性、标准化试验中,研究低剂量静脉注射甲氨蝶呤(MTX)联合或不联合糖皮质激素(GC)用于维持全身性韦格纳肉芽肿(WG)患者缓解的长期疗效。
在通过环磷酰胺和GC诱导缓解后,71例(41例男性,30例女性)初发全身性WG患者接受每周一次0.3mg/kg体重的低剂量甲氨蝶呤治疗。研究开始时,71例患者中有55例(77.5%)接受低剂量GC治疗(平均5.9mg/天),在研究过程中逐渐减量。所有患者每3个月(之后每6个月)进行一次多学科分期,以评估疾病活动度、范围及副作用。终点为首次复发或研究结束(2001年1月)。
在平均25.2个月的随访期内,26例患者(36.6%)在平均19.4个月后复发。这26例患者中有17例(65.4%)在复发时已停用GC治疗。研究开始时联合或未联合GC治疗的患者复发率无差异。复发主要发生在最初受累的器官系统,26例患者中有18例优先累及耳、鼻、喉,16例累及肾脏。1例肾脏复发表现为快速进展性肾小球肾炎,导致死亡。此外,14例复发伴有肌酐值显著升高。26例患者中有15例复发时抗中性粒细胞胞浆抗体滴度显著升高或在复发前升高。2例患者因持续性白细胞减少而提前停用MTX。
每周一次的MTX是一种耐受性良好的长期维持缓解治疗方法。然而,三分之一的患者在MTX持续治疗期间复发,无论他们是否仍在接受GC治疗。由于超过一半的复发累及肾脏,密切监测必不可少。